Core Points - Haiyou New Materials announced that CITIC Construction Investment will continue to act as the sponsor for the company's issuance of convertible bonds to unspecified objects, with the continuous supervision period extending until December 31, 2024 [2] - Due to the company's unutilized fundraising, CITIC Construction Investment will fulfill its ongoing supervisory obligations as per relevant regulations [2] - The original sponsor representatives, Li Pengfei and Shen Qian, have been replaced due to Li Pengfei's job transfer, with Ren Yuntao appointed to ensure the orderly continuation of supervisory work [2]

Core Insights - The core viewpoint emphasizes that technological finance is not merely about capital injection but requires specialized, systematic, and innovative services to address the financing challenges faced by tech innovation enterprises [1] Group 1: Financing Challenges - Technological innovation enterprises face high R&D costs, strong frontier attributes, long cycles, and significant risks, making superficial analysis inadequate for comprehensive value assessment [1] - There is a need for deep research to penetrate the complexities and identify genuine innovative resources [1] Group 2: Research and Development - The company aims to deepen industry-wide research and build a value discovery network, leveraging its traditional research-driven advantages [1] - The research team covers emerging fields such as artificial intelligence, biomedicine, new energy, and high-end manufacturing, focusing on the forefront dynamics of technological innovation [1] Group 3: Business Model - The company is developing a "Golden Triangle" business model to connect research value transformation [1] - Celebrating its 20th anniversary, the company has consistently focused on its core responsibilities, establishing a competitive edge through the investment banking, investment, and research model [1] - The company aims to enhance its investment banking capabilities and industry research capabilities in alignment with the development of the real economy [1]

Core Viewpoint - CITIC Securities reports that Kangfang Biopharma (09926) has multiple products and indications in its pipeline that are expected to be approved for market entry, indicating a strong long-term sustainable development capability [1] Group 1: Pipeline and Product Development - Kangfang Biopharma's research pipeline is expanding, with a rich reserve of early-stage products [1] - The approval of Iwosimab for market entry contributes to the company's sales growth, while the sales revenue from its products is increasing year by year [1] - The company is rated as "Buy" due to the excellent efficacy of its innovative drug products and the broad market potential [1] Group 2: Clinical Trial Results - At the 2025 SITC, Kangfang Biopharma presented the final overall survival (OS) results of the HARMONi-A trial, showing a median follow-up time of 32.5 months, with an OS hazard ratio (OSHR) of 0.74 (0.58-0.95) (P=0.019) for the Iwosimab treatment group compared to the control group [1] - This trial is noted as the first to achieve clinically meaningful and statistically significant benefits in both progression-free survival (PFS) and OS for an immunotherapy in patients with EGFR TKI-pretreated non-small cell lung cancer (NSCLC) [1] Group 3: Future Focus Areas - Future attention can be directed towards the final OS results update for Iwosimab in the domestic HARMONi-2 trial and the submission of the BLA application in the U.S. [2] - Ongoing global clinical trials for AK104 targeting first-line gastric cancer, second-line IO-resistant hepatocellular carcinoma, and PD-L1 negative NSCLC are also noteworthy [2] - The advancement of AK132 (Claudin18.2/CD47), AK137 (CD73/LAG3) into Phase II clinical trials, and the IND application for AK150 (ILT2/ILT4/CSF1R) are significant developments [2]

Core Viewpoint - CITIC Securities reports that Kangfang Biopharma (09926) has multiple products and indications in its pipeline nearing approval, with a continuously expanding R&D pipeline and a strong early-stage pipeline, indicating long-term sustainable development capability [1] Group 1: Product Pipeline and R&D - Kangfang Biopharma is expected to present final overall survival (OS) results for HARMONi-A at the 2025 SITC, with a median follow-up of 32.5 months showing an OS hazard ratio (OSHR) of 0.74 (0.58-0.95) (P=0.019) [1] - The company has achieved significant clinical and statistical benefits in its Phase III clinical trial for an immunotherapy that targets EGFR TKI-treated non-small cell lung cancer (NSCLC) [1] Group 2: Sales Performance - The approval of the drug Iwosimab has contributed to incremental sales for the company, while the sales of the drug Kantan have shown stable growth, leading to an annual increase in product sales revenue [1] Group 3: Future Focus Areas - Future attention can be directed towards the final OS results update for Iwosimab in the domestic HARMONi-2 trial, the submission of the BLA application in the U.S., and the overseas mPFS analysis for HARMONi-32026 in the second half of 2026 [2] - Ongoing global clinical trials for AK104 targeting first-line gastric cancer, second-line IO-resistant hepatocellular carcinoma, and PD-L1 negative NSCLC are also noteworthy [2] - The advancement of AK132 (Claudin18.2/CD47), AK137 (CD73/LAG3) into Phase II clinical trials, and the IND application for AK150 (ILT2/ILT4/CSF1R) are significant developments [2]

格隆汇11月13日｜中信建投证券研报指出，迈瑞医疗Q3业绩符合预期，收入增速如期转正，利润端受 毛利率下降、费用率提升影响有所承压。Q4收入增速预计较Q3进一步提升，Q4利润预计在低基数下实 现增长，但考虑到前三季度利润下滑幅度较大，且今年整体利润率承压，预计全年公司归母净利润将有 双位数下滑。展望明年，预计公司将走出行业外部压力带来的影响，回归收入、利润稳健增长轨道。中 长期来看，公司重视研发创新和国际化，拥有高效的研发体系和优秀的渠道管理能力，外延并购有望进 一步拓展布局，加上公司国际化进度持续推进，该行看好公司未来加快迈向全球医疗器械Top10 公司的 步伐。维持"买入"评级。 ...

Group 1 - The core viewpoint of the news is that Aofei Data's stock has seen a significant increase of 5.39%, reaching a price of 19.74 CNY per share, with a trading volume of 666 million CNY and a turnover rate of 3.55%, resulting in a total market capitalization of 19.447 billion CNY [1] - Aofei Data, established on September 28, 2004, and listed on January 19, 2018, primarily operates in the Internet Data Center (IDC) sector, with IDC services accounting for 82.18% of its revenue and other internet services making up 17.82% [1] Group 2 - From the perspective of major fund holdings, a fund under CITIC Jiantou has Aofei Data as its sixth-largest holding, with a reduction of 45,700 shares in the third quarter, leaving 250,000 shares, which represents 3.56% of the fund's net value [2] - The CITIC Jiantou Technology Theme 6-Month Holding Mixed A fund (017034) has experienced a loss of 5.34% this year, ranking 8097 out of 8145 in its category, and a loss of 17.08% over the past year, ranking 8038 out of 8059 [2]

Core Viewpoint - The 2026 GDP growth target for China is set at around 5%, which is deemed necessary and feasible to stabilize investor confidence in Chinese assets and capital markets [1][3]. Group 1: Economic Growth Projections - The chief economist of CITIC Securities, Huang Wentao, indicated that China's GDP growth is expected to reach around 5% next year due to policy support [1]. - The average GDP growth rate required from 2020 to 2035 to achieve the goal of reaching the per capita GDP of a moderately developed country by 2035 is approximately 4.73% [1]. - The average GDP growth rate during the 14th Five-Year Plan period is above 5%, meeting the stage requirements [1]. Group 2: Export and External Demand - Huang noted that external demand remains resilient, with China's export performance in 2025 exceeding expectations, contributing over 30% to GDP growth in the first half of the year [2]. - If the trade agreements are effectively executed and non-U.S. economies continue to expand, the export growth rate in 2026 is expected to exceed expectations [3]. Group 3: Real Estate Market Outlook - The negative impact of the real estate sector on the economy is expected to diminish, with a projected slight narrowing of the decline in real estate development investment and new housing sales in 2026 [3]. - The decline in new housing sales is anticipated to be within 5%, reducing the negative drag on the economy [3]. Group 4: Policy Support and Consumer Recovery - There is ample room for policy support, with fiscal, monetary, and industrial policies expected to work in tandem in 2026 [3]. - The implementation of "two重" and "two新" policies is expected to continue, with an increase in support for service consumption and the expansion of trade-in policies for consumer goods [3]. - If fiscal policies align with consumer recovery efforts, consumption is projected to improve from its current low state [3].

Core Points - Softcom Power has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific investors [1] - The total amount to be raised from this issuance is not more than RMB 334,832.03 million, which will be used for various projects including the Beijing-Tianjin-Hebei Soft Communication Intelligent Manufacturing Base [1][2] - The issuance will involve up to 285,882,353 shares, representing no more than 30% of the total share capital prior to the issuance [2] Summary by Sections - **Issuance Approval** - The Shenzhen Stock Exchange's listing review center has deemed that Softcom Power meets the conditions for issuing shares [1] - The final approval from the China Securities Regulatory Commission (CSRC) is still pending, introducing uncertainty regarding the timing and outcome of the registration [1] - **Details of the Share Issuance** - The shares will be domestic RMB ordinary shares (A-shares) with a par value of RMB 1.00 each [2] - The issuance will target no more than 35 specific investors, including qualified institutional investors and other eligible entities [2] - The pricing will be based on the average trading price over the 20 trading days prior to the pricing benchmark date, with a minimum price set at 80% of that average [2] - **Sponsorship** - The sponsor for this issuance is CITIC Securities Co., Ltd., with representatives Xu Jie and Chen Zehao [3]

11月13日，索通发展涨5.41%，截至发稿，报30.57元/股，成交7.62亿元，换手率5.15%，总市值152.27 亿元。 截至发稿，艾翀累计任职时间8年21天，现任基金资产总规模3.12亿元，任职期间最佳基金回报 91.88%， 任职期间最差基金回报-23.39%。 杨志武累计任职时间2年346天，现任基金资产总规模4.19亿元，任职期间最佳基金回报46.35%， 任职 期间最差基金回报7.35%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中信建投基金旗下1只基金重仓索通发展。中信建投睿利A（003308）三季度增持3100股， 持有股数1.06万股，占基金净值比例为0.49%，位居第一大重仓股。根据测算，今日浮盈赚取约1.66万 元。 中信建投睿利A（003308）成立日期2016年12月7日，最新规模1369.26万。今年以来收益43.82%，同类 排名1411/8145；近一年收益40.09%，同类排名1049/8059 ...

Core Viewpoint - The Shanghai Stock Exchange's Listing Review Committee approved the initial public offering (IPO) of Qiangyi Semiconductor (Suzhou) Co., Ltd., marking it as the 73rd company to pass the review this year, with a total of 44 companies from the Shanghai and Shenzhen stock exchanges and 29 from the Beijing Stock Exchange [1]. Company Overview - Qiangyi Semiconductor is a high-tech enterprise focused on semiconductor design and manufacturing, specifically in the research, design, production, and sales of wafer testing core hardware probe cards [2]. - The controlling shareholder and actual controller of Qiangyi Semiconductor is Zhou Ming, who directly holds 27.93% of the shares and indirectly controls an additional 13.83%, totaling 50.05% control over the company [2]. - The company plans to list on the Sci-Tech Innovation Board of the Shanghai Stock Exchange, with a public offering of up to 32.39 million shares, representing no less than 25% of the total share capital post-issuance [2]. Fundraising and Use of Proceeds - Qiangyi Semiconductor aims to raise 1.5 billion yuan (approximately 150 million) through this IPO, which will be allocated to the development and production of probe cards in Nantong and the construction of its headquarters and R&D center in Suzhou [2]. Listing Review Committee Inquiries - The Listing Review Committee raised inquiries regarding the company's significant reliance on major clients, the independence and sustainability of its business and R&D, and measures taken to mitigate risks associated with dependence on a single related client [3]. - The committee also questioned the assessment of revenue forecasts related to major clients and the fairness of related transactions [3].